Traduction de «the famhp will need » (Néerlandais → Français) :

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.
Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.

During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.
During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.

Finally, the implementation of the new structure of the FAMHP will have a considerable impact on the Veterinary Medicines unit, as the current powers/responsibilities relating to the PRE and POST pillars will be redistributed.
Finally, the implementation of the new structure of the FAMHP will have a considerable impact on the Veterinary Medicines unit, as the current powers/responsibilities relating to the PRE and POST pillars will be redistributed.

This growth will continue in 2008, and the FAMHP will pass the 8,000 mark for import-export licences.
This growth will continue in 2008, and the FAMHP will pass the 8,000 mark for import-export licences.

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.
The law of 7 May 2004 relating to experiments on the human person in Belgium provides that any objections from the FAMHP need to be submitted within a maximum of 28 days following the validation of applications for clinical trials.

This merger, which will be implemented under the Swiss Merger Act, is in the interest of all stakeholders and will provide the needed clarity on Alcon’s future.
Cette fusion, qui sera réalisée conformément à la loi fédérale sur la fusion, est dans l'intérêt de toutes les parties prenantes en clarifiant l’avenir d’Alcon.

Medicines discovered by the institute will be made available at cost to poor patients in those countries where they are most needed.
Les médicaments mis au point par l’Institut seront fournis à prix coûtant aux malades pauvres des pays où les besoins sont les plus urgents.

Novartis believes this merger, which is governed under the Swiss Merger Act, is in the interest of all stakeholders and will provide the needed clarity on Alcon’s future.
Novartis est convaincu que cette fusion, qui sera réalisée conformément à la loi fédérale suisse sur la fusion, est dans l’intérêt de toutes les parties prenantes en apportant la clarté nécessaire à l’avenir d’Alcon.